Skip to content
OpenCapital
Get started
DMA

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA

Drugs Made In America Acquisition Corp. is a blank check company, also known as a special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, share exchange, or similar business combination.

Market cap
$258.55M-24.3%

Table of contents

Competitors

By market cap

GPA
GP-Act III Acquisition Corp.$390.6M+3.0%
RNG
Range Capital Acquisition Corp II $316.7M—
DMA
Drugs Made In America Acquisition Corp. Ordinary Shares$258.5M-24.3%
NTW
Newbury Street II Acquisition Corp Class A Ordinary Shares$256.6M+3.4%
HAV
Harvard Ave Acquisition Corporation $209.0M—
RAN
Range Capital Acquisition Corp. Ordinary Shares$171.5M+4.4%
LAF
LaFayette Acquisition Corp. $158.4M—
UAC
United Acquisition Corp $137.6M—

Profile

Drugs Made In America Acquisition Corp. is a blank check company, also known as a special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, share exchange, or similar business combination. The company focuses on identifying and acquiring high-growth businesses within the artificial intelligence, pharmaceutical, and technology sectors that demonstrate a need for rapid innovation. Its primary value proposition is providing a target entity with a public listing and capital to accelerate growth and operational expansion.

Competitive position

The company is a shell entity with nominal assets and no operating history, competing with numerous other SPACs and private equity firms for high-quality acquisition targets.

GeographiesUnited States, Cayman Islands
Customer segmentsInstitutional Investors, Retail Investors
Business modelSPAC
SuppliersInvestment Banks, Legal Counsel, Audit and Accounting Firms, Sponsor Capital
CustomersTarget Acquisition Businesses, Public Equity Markets
CountryUnited States of America
Listed2025
CEORoger Bendelac
FilingsSEC EDGAR

Questions, answered.

What is Drugs Made In America Acquisition Corp. Ordinary Shares's market cap?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a market capitalization of $258.5M and trades on NASDAQ.
Who are Drugs Made In America Acquisition Corp. Ordinary Shares's competitors?
Drugs Made In America Acquisition Corp. Ordinary Shares's key competitors include United Acquisition Corp. I, GP-Act III Acquisition Corp. Class A Ordinary Share, Range Capital Acquisition Corp. Ordinary Shares, and others. These companies compete in similar markets and product categories.
Who does Drugs Made In America Acquisition Corp. Ordinary Shares partner with?
Drugs Made In America Acquisition Corp. Ordinary Shares's notable partners include Clear Street LLC, BV Advisory Partners, LLC, Wilmington Trust, National Association, and others.
Where is Drugs Made In America Acquisition Corp. Ordinary Shares headquartered?
Drugs Made In America Acquisition Corp. Ordinary Shares is headquartered in United States of America. It has been publicly traded since 2025.